Abstract
Two common polymorphisms in the β1-adrenergic receptor gene, Ser49Gly and Arg389Gly, are associated with variable antihypertensive response to metoprolol. We sought to determine whether similar pharmacogenetic associations were present with the negative chronotropic response phenotype to metoprolol. Metoprolol was titrated in 54 untreated hypertensive patients to achieve blood pressure control. We found no association between either resting or exercise heart rate at baseline (untreated) or in response to metoprolol by codon 389 genotype. In contrast, when compared by codon 49 genotype, Ser49 homozygotes had significantly higher resting heart rates at baseline (untreated) than Gly49 carriers (82±10 versus 74±11 bpm, respectively, P=0.016). When corrected for plasma concentration, we found no difference in reduction in exercise heart rate in response to metoprolol between Ser49 homozygotes and Gly49 carriers (0.75±0.11 versus 0.57±0.17%/ng/ml, respectively, P=0.37). However, if one fails to account for plasma concentration, trends toward a significant difference in heart rate reduction are seen between Ser49 homozygotes and Gly49 carriers (31% reduction versus 25% reduction, P=0.05). Our data suggest that neither the β1-adrenergic receptor Arg389Gly, nor the Ser49Gly polymorphisms are associated with variable negative chronotropic response to metoprolol. In addition, our data highlight the importance of measuring metoprolol concentration in order to account for variable pharmacokinetics and avoid misinterpretation of the data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mason DA, Moore JD, Green SA, Liggett SB . A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670–12674.
Rathz DA, Brown KM, Kramer LA, Liggett SB . Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155–160.
Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF . Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44–52.
Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372–379.
Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73: 366–371.
La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P . The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics 2004; 14: 711–716.
Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77: 127–137.
Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005; 15: 227–234.
Xie HG, Dishy V, Sofowora G, Kim RB, Landau R, Smiley RM et al. Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191–197.
Buscher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S et al. In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11: 199–205.
Ranade K, Jorgenson E, Sheu WH, Pei D, Hsiung CA, Chiang FT et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935–942.
O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ . The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (London) 2000; 99: 233–238.
Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL et al. Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001; 88: 1034–1037.
de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, Foucher-Hossein C et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005; 15: 137–142.
Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2005: 1–6, [E-Pub ahead of print].
Monteleone P, Santonastaso P, Tortorella A, Favaro A, Fabrazzo M, Castaldo E et al. Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. Mol Psychiatr 2005; 10: 716–718.
Yang L, Wang YF, Li J, Faraone SV . Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatr 2004; 43: 1154–1158.
Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW . Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30: 1719–1723.
Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394–1399.
Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536–544.
Johnson JA, Akers WS, Miller ST, Applegate WB . Metoprolol minimizes nighttime blood pressure dip in hypertensive black males. Am J Hypertens 1995; 8: 254–259.
Johnson JA, Burlew BS . Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996; 24: 350–355.
Maqbool A, Hall AS, Ball SG, Balmforth AJ . Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet 1999; 353: 897.
Acknowledgements
We would like to gratefully acknowledge Kathy Eberst for her expert HPLC analytic assistance and Dr Hartmut Derendorf for his insightful comments regarding the manuscript. This study was supported by NIH Grants HL64691, HL68834, and by the University of Florida GCRC Grant RR00082.
Author information
Authors and Affiliations
Corresponding author
Additional information
Duality of Interest
The study sponsor had no involvement in study design, data collection, analysis, or interpretation, writing of the paper, or the decision to submit the paper for publication.
Rights and permissions
About this article
Cite this article
Beitelshees, A., Zineh, I., Yarandi, H. et al. Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics. Pharmacogenomics J 6, 174–178 (2006). https://doi.org/10.1038/sj.tpj.6500354
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500354
Keywords
This article is cited by
-
Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method
Human Genomics (2016)
-
Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study
Clinical Pharmacology & Therapeutics (2009)
-
Pharmakogenetik in der Kardiologie
Der Kardiologe (2007)